Navigation Links
China Yingxia International Announces 2007 Fourth Quarter and Full Year Financial Results Conference Call
Date:3/26/2008

as amended, and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as 'believes,' 'expects,' 'may,' 'will,' 'should,' or 'anticipates' or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding the potential growth of the markets are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including but not limited to, general economic conditions and regulatory developments, not within our control. The factors discussed herein and expressed from time to time in our filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed or implied by such statements. The forward-looking statements are made only as of the date of this filing, and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

For more information, please contact:

Peter Zhou

Tel: +1-212-232-0058


'/>"/>
SOURCE China Yingxia International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. China Medicine Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
2. China RuiTai International Holdings Retains CCG Elite for Investor Relations Services
3. China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents
4. Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China
5. China Nepstar Chain Drugstore Announces Dividend
6. Alsius Corporation Receives Regulatory Approval in China and Mexico
7. Mirion Technologies to Showcase New Product Offerings for the Nuclear Industry During 10th Annual China International Nuclear Industry Exhibition
8. China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007
9. Flagship Global Health and China HealthCare Holdings Form Strategic Alliance
10. Perot Systems and ChinaSoft to Pursue Chinese Healthcare Opportunities
11. China Nepstar Chain Drugstore to Announce Fourth Quarter 2007 Financial Results on March 19
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Beverage Can Stay Tabs Pose Swallowing Risk 62223 1Beverage Can Stay Tabs Pose Swallowing Risk 62223 2New Class of Platinum Based Anti Tumor Drugs Bisplatinates Demonstrates Potent Anti Tumor Activity and Ability to Overcome Resistance to Currently A 14993 1New Class of Platinum Based Anti Tumor Drugs Bisplatinates Demonstrates Potent Anti Tumor Activity and Ability to Overcome Resistance to Currently A 14993 2New Class of Platinum Based Anti Tumor Drugs Bisplatinates Demonstrates Potent Anti Tumor Activity and Ability to Overcome Resistance to Currently A 14993 3Elsevier is Re Launching 26quot 3BEmbase 26quot 3B to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 14989 1Elsevier is Re Launching 26quot 3BEmbase 26quot 3B to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 14989 2Elsevier is Re Launching 26quot 3BEmbase 26quot 3B to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 14989 3